Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Receivables (2023 - 2024)

Historic Receivables for Capricor Therapeutics (CAPR) over the last 3 years, with Q4 2024 value amounting to $20.4 million.

  • Capricor Therapeutics' Receivables fell 1.72% to $20.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $20.4 million, marking a year-over-year decrease of 1.72%. This contributed to the annual value of $20.4 million for FY2024, which is 1.72% down from last year.
  • Per Capricor Therapeutics' latest filing, its Receivables stood at $20.4 million for Q4 2024, which was down 1.72% from $20.4 million recorded in Q4 2023.
  • Capricor Therapeutics' 5-year Receivables high stood at $20.4 million for Q4 2023, and its period low was $20.4 million during Q4 2024.